Author:
Ni Jie,Cozzi Paul J.,Duan Wei,Shigdar Sarah,Graham Peter H.,John Kearsley H.,Li Yong
Publisher
Springer Science and Business Media LLC
Reference105 articles.
1. Beltran, H., Beer, T. M., Carducci, M. A., de Bono, J., Gleave, M., Hussain, M., et al. (2011). New therapies for castration-resistant prostate cancer: efficacy and safety. European Urology, 60, 279–290.
2. Logothetis, C. J. (2002). Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology (Williston Park, N.Y.), 16(6 Suppl 6), 63–72.
3. Petrylak, D. P., Tangen, C. M., Hussain, M. H., Lara, P. N., Jr., Jones, J. A., Taplin, M. E., et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England Journal of Medicine, 351(15), 1513–1520.
4. Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine, 351, 1502–1512.
5. Calabro, F., & Sternberg, C. N. (2007). Current indications for chemotherapy in prostate cancer patients. European Urology, 51, 17–26.
Cited by
71 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献